>>Signaling Pathways>> GPCR/G protein>> Adenosine Receptor>>A2AR-agonist-1

A2AR-agonist-1 (Synonyms: JMF 1907)

Catalog No.GC30987

A2AR-작용제-1은 A2AR 및 ENT1에 대해 Ki가 4.39 및 3.47인 강력한 A2AR 및 ENT1 작용제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

A2AR-agonist-1 Chemical Structure

Cas No.: 41552-95-8

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$354.00
재고 있음
5mg
US$321.00
재고 있음
10mg
US$459.00
재고 있음
50mg
US$1,379.00
재고 있음
100mg
US$1,930.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

A2AR-agonist-1 is a potent A2AR and ENT1 agonist with Ki of 4.39 and 3.47 for A2AR and ENT1.IC50 value: 4.39 and 3.47 (Ki) [1]Target: A2AR and ENT1A2AR-agonist-1 is a novel dual-action compound, targeting the Adenosine A2A Receptor and Adenosine Transporter for Neuroprotection.[1]

[1]. Chen JB, et al. Design and synthesis of novel dual-action compounds targeting the adenosine A(2A) receptor and adenosine transporter for neuroprotection. ChemMedChem. 2011 Aug 1;6(8):1390-1400. [2]. Lin Yun-Lian, et al. Dual-action compounds targeting adenosine A2A receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases. From PCT Int. Appl. (2012), WO 2012064340 A1 20120518. [3]. Chen, Chih-Cheng, et al. Methods and compositions for treating pain. From PCT Int. Appl. (2013), WO 2013120078 A1 20130815.

리뷰

Review for A2AR-agonist-1

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for A2AR-agonist-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.